Hoth Therapeutics rises as early obesity‑drug data in mice shows promise

Rocket One

10/02/2026 14:27

** Shares of Hoth Therapeutics HOTH.O rise 3.9% to $0.89 premarket

**  Co says its experimental obesity drug HT‑VA GDNF helped mice gain less weight and stabilize weight compared with semaglutide

** Co says the drug also improved blood sugar and reduced liver weight, which could help fatty liver disease — a liver condition linked to obesity

** The 12‑week study was conducted in female mice placed on a high‑fat diet, in collaboration with the U.S. Veterans Administration

** Co says it plans to start human trials in 2027 and is also developing treatments for cancer‑related skin problems and Alzheimer’s

** Shares up ~32% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))